, Volume 51, Issue 6, pp 974-980
Date: 31 Oct 2012


Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


▴ Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity

▴ It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastroprotective action against ethanol-, aspirin- or stress-induced gastric mucosal damage

▴ The antisecretory properties of ebrotidine are similar to those of ranitidine and ≈ 10-fold greater than those of Cimetidine

▴ This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipopolysaccharide

▴ Ebrotidine is as effective as ranitidine for the treatment of patients with gastric or duodenal ulcers or erosive reflux oesophagitis

▴ Ebrotidine therapy results in significantly better ulcer healing rates than ranitidine treatment in patients who smoke.